Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Mogamulizumab

            Therapeutic Area: Oncology Product Name: Poteligeo

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 06, 2020

            Details:

            The findings showed patients who achieved a long-term (> 12 months) response with mogamulizumab treatment were more likely to have Sézary syndrome (stage IVA1) or blood involvement compared to patients with an ORR of shorter duration.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Cabozantinib

            Therapeutic Area: Oncology Product Name: Cabometyx

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Exelixis

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 27, 2020

            Details:

            The CELESTIAL trial was the basis for the CABOMETYX approvals in the U.S. and the EU for the treatment of patients with HCC who have been previously treated with sorafenib.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Gilteritinib

            Therapeutic Area: Oncology Product Name: Xospata

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 16, 2020

            Details:

            Oral presentations include new data on the use of gilteritinib, either as monotherapy or in combination, across the FLT3mut+ AML patient spectrum – from those newly diagnosed, to relapsed or refractory patients who have been pre-treated with other tyrosine kinase inhibitors.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Atezolizumab

            Therapeutic Area: Oncology Product Name: Tecentriq

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: F. Hoffmann-La Roche

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement November 09, 2020

            Details:

            ONO and Bristol Myers Squibb gains Roche's Tecentriq (atezolizumab), a monoclonal antibody designed to bind with a protein called PD-L1 expressed on tumour cells and tumour-infiltrating immune cells.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Trastuzumab Deruxtecan

            Therapeutic Area: Oncology Product Name: Enhertu

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: AstraZeneca PLC

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 02, 2020

            Details:

            DESTINY-Breast05 is a phase 3 active-controlled study of ENHERTU versus T-DM1 in patients with high-risk HER2 positive primary breast cancer who have residual invasive disease in breast or axillary lymph nodes following neo-adjuvant therapy.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Enfortumab vedotin-ejfv

            Therapeutic Area: Oncology Product Name: Padcev

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Seagen

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 13, 2020

            Details:

            The cohort is evaluating the antibody-drug conjugate PADCEV® for patients with locally advanced or metastatic urothelial cancer who have been previously treated with a PD-1/L1 inhibitor and have not received a platinum-containing chemotherapy and are ineligible for cisplatin.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Atezolizumab,Bevacizumab

            Therapeutic Area: Oncology Product Name: Tecentriq

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 25, 2020

            Details:

            Chugai has obtained approval for an additional indication of Tecentriq® Intravenous Infusion 1200 mg and Avastin® Intravenous Infusion 100 mg/4 mL and 400 mg/16 mL for the treatment of unresectable hepatocellular carcinoma from the Ministry of Health, Labour and Welfare.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Trastuzumab Deruxtecan

            Therapeutic Area: Oncology Product Name: Enhertu

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 25, 2020

            Details:

            ENHERTU is the first and only HER2 directed medicine to demonstrate significant improvement in overall survival compared to chemotherapy for patients with previously treated HER2 positive advanced gastric cancer.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Nivolumab,Ipilimumab

            Therapeutic Area: Oncology Product Name: Opdivo

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Bristol-Myers Squibb

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 25, 2020

            Details:

            This approval is mainly based on the result from the Opdivo and Yervoy combination therapy cohort of a multicenter, open-label Phase II clinical study conducted by Bristol Myers Squibb in patients with MSI-High or deficient mismatch repair (dMMR).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Trastuzumab emtansine

            Therapeutic Area: Oncology Product Name: Kadcyla

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 21, 2020

            Details:

            Approval is based on the study which evaluated the efficacy and safety of Kadcyla adjuvant therapy in patients with HER2-positive early breast cancer who did not have pathologic complete response following neoadjuvant therapy including Herceptin.